

**Robert J. Meyer, M.D.**

Since June 2002 Dr. Meyer has been Director of the Office of Drug Evaluation II, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA). This Office comprises the Division of Pulmonary and Allergy Products; the Division of Anesthesia, Analgesia, and Rheumatologic Products; and the Division of Metabolic and Endocrine Products. In addition to his work within the Office of New Drugs, Dr. Meyer is involved in a number of Center- and Agency-level activities, including chairing the Agency's Risk Assessment Guidance working group (PDUFA III Risk Management Guidances), serving on the FDA's Interdisciplinary Pharmacogenomics Research Group, and serving as an alternate member of the FDA's Drug Safety Oversight Board. Dr. Meyer is also a member of the Aerosol Technical Options Committee of the United Nations Environmental Programme. He joined the FDA as a medical reviewer in the Division of Oncologic and Pulmonary Drug Products in July 1994, where he became a clinical team leader in 1996. Dr. Meyer was named Director of the division (now called the Division of Pulmonary and Allergy Drug Products) in 1999.

He came to the FDA from the Oregon Health & Science University (OHSU) in Portland, where he was Assistant Professor of Medicine in the Pulmonary and Critical Care Division and was Co-Medical Director of Lung and Heart/Lung Transplantation at OHSU. Dr. Meyer received his B.A. degree in natural science from Lehigh University in 1980 and his M.D. degree from the University of Connecticut Medical School in 1984. He completed a residency in internal medicine (1984-1987) and a chief medical residency (1987-1988) at the University of Connecticut, Newington, Veterans Affairs Medical Center Internal Medicine Program. Dr. Meyer Office of AIDS Research then performed a fellowship in pulmonary and critical care medicine (1988-1991) at the University of Vermont.